Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.57 |
| ▸ | BTK | Q06187 | 5/20 | 0.57 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.51 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.43 |
| ▸ | S100A10 | P60903 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204660 | 0.88 | EGFR (0.56) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL2778210 | 0.88 | EGFR (0.56) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL2778207 | 0.88 | EGFR (0.56) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL692000 | 0.84 | EGFR (0.52) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL691999 | 0.84 | EGFR (0.52) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL12310629 | 0.82 | PIP4K2A (0.60) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL21443460 | 0.81 | EGFR (0.86) | EGFRBTKITK | |
| SCHEMBL690637 | 0.81 | PIP4K2A (0.59) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL690638 | 0.81 | PIP4K2A (0.59) | EGFRBTKPIP4K2APIP4K2BERBB2 | |
| SCHEMBL13883499 | 0.81 | PIP4K2A (0.59) | EGFRBTKPIP4K2APIP4K2BERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9393246-B2 | 4,6-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9393246-B2 | 4,6-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9393246-B2 | 4,6-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2010123870-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2214486-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885PIP4K2A 3115/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885PIP4K2A 3115/4885 |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885PIP4K2A 3115/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885PIP4K2A 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.